Sofamor buys carbon fibre fusion device maker:
This article was originally published in Clinica
Sofamor Danek is to acquire the carbon fibre subsidiary of the German MAN group, for an undisclosed amount. MAN Ceramics makes carbon fibre interbody fusion devices. While cervical and lumbar forms of the device have been used in more than 1,400 procedures over the past five years in Europe, the cages have not yet received FDA approval.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.